Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives

Blocking the MDM2/X–P53 protein–protein interaction has been widely recognized as an attractive therapeutic strategy for the treatment of cancers. Numerous small-molecule MDM2 inhibitors have been reported since the release of the structure of the MDM2–P53 interaction in 1996, SAR405838, NVP-CGM097,...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Yuan, Liao, Guochao, Yu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452049/
https://www.ncbi.nlm.nih.gov/pubmed/32874827
http://dx.doi.org/10.1016/j.apsb.2020.01.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452049/
https://www.ncbi.nlm.nih.gov/pubmed/32874827
http://dx.doi.org/10.1016/j.apsb.2020.01.003

Ejemplares similares